Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AstraZeneca
Biotech
Eolas regains opioid use disorder drug abandoned by AstraZeneca
AZ ended work on the orexin 1 receptor antagonist in November after a phase 2 study identified a “potential drug-drug interaction" with itraconazole.
James Waldron
Jul 10, 2025 9:33am
AstraZeneca’s Alexion pens $825M AAV capsid pact with JCR
Jul 9, 2025 4:52am
Biotech shares first data for in vivo CAR-T that attracted AZ
Jul 7, 2025 2:27pm
Fierce Pharma
Summit in high-stakes deal talks with AstraZeneca: Bloomberg
Jul 7, 2025 10:45am
How 'overenthusiasm' led to Big Pharma's risky $6B TIGIT gamble
Jun 13, 2025 8:00am
AstraZeneca pens $5.3B pact with CSPC to develop oral drugs
Jun 13, 2025 5:56am
